NASDAQ: NUWENuwellis Inc Stock
$5.22-0.07 (-1.32%)
Updated Aug 22, 2025
NUWE Price
$5.22
Fair Value Price
N/A
Market Cap
$4.71M
52 Week Low
$4.82
52 Week High
$175.98
P/E
0.02x
P/B
-0.53x
P/S
0.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.32M
Earnings
-$14.68M
Gross Margin
60.5%
Operating Margin
-49.51%
Profit Margin
-176.4%
Debt to Equity
-2.03
Operating Cash Flow
-$9M
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NUWE Overview
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NUWE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important NUWE news, forecast changes, insider trades & much more!
NUWE News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NUWE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NUWE is good value based on its earnings relative to its share price (0.02x), compared to the US market average (35.55x)
P/E vs Market Valuation
NUWE is good value based on its earnings relative to its share price (0.02x), compared to the US Medical Devices industry average (32.47x)
P/E vs Industry Valuation
NUWE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NUWE due diligence checks available for Premium users.
Valuation
NUWE fair value
Fair Value of NUWE stock based on Discounted Cash Flow (DCF)
Price
$5.22
Fair Value
-$3.18
Undervalued by
264.37%
NUWE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.02x
Industry
32.47x
Market
35.55x
NUWE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NUWE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
NUWE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.53x
Industry
4.09x
NUWE's financial health
Profit margin
Revenue
$1.7M
Net Income
-$12.6M
Profit Margin
-727.7%
NUWE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NUWE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.2M
Liabilities
$18.2M
Debt to equity
-2.03
NUWE's short-term assets ($8.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NUWE's long-term liabilities ($14.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NUWE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NUWE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
-$4.0k
Financing
$4.0M
NUWE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NUWE vs Medical Device Stocks
Nuwellis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.